Addex Therapeutics Partners with Sinntaxis for Recovery in Brain Injuries
Addex Therapeutics, a clinical-stage biopharmaceutical innovator, has taken a significant step forward by establishing an option and collaboration agreement with Sinntaxis. This partnership revolves around the exclusive licensing of essential intellectual property related to metabotropic glutamate receptor subtype 5 (mGlu5) inhibitors, aiming to support recovery in individuals experiencing brain injuries.
Understanding the Agreement
The collaboration between Addex and Sinntaxis signifies a strategic move for Addex, which aims to leverage the potential of its key asset, dipraglurant. This drug is categorized as an mGlu5 negative allosteric modulator (NAM) and is under evaluation for its effectiveness in brain injury recovery. Tim Dyer, CEO of Addex, emphasized the importance of this agreement in addressing unmet medical needs in the recovery of brain function, particularly after incidents like strokes or traumatic injuries.
As part of the agreement, Addex will provide an undisclosed fee to Sinntaxis for the licensing rights to intellectual property that covers the use of mGlu5 NAMs. This licensing will enable the continuous development and evaluation of dipraglurant while adding valuable expertise from Sinntaxis in clinical planning and execution of research initiatives.
Collaboration Fostering Research Innovation
Sinntaxis’s involvement is particularly beneficial, given their expertise in understanding the mGlu5 receptor's role in enhancing brain plasticity and function. Tadeusz Wieloch, CEO of Sinntaxis, expressed eagerness to contribute to the collaborative efforts, highlighting the need for reliable clinical candidates that can effectively assist patients recovering from brain injuries.
The Science Behind mGlu5 Inhibitors
Research indicates that functional recovery from strokes heavily depends on the brain's ability to form new neural connections or reactivate existing ones. The mGlu5 receptor plays a crucial role in modulating brain plasticity, and recent studies have shown promising results for mGlu5 NAMs.
One noteworthy study published in the journal Brain illustrated that daily treatment with mGlu5 NAMs administered after strokes significantly restored somatosensory functions without increasing infarct size. The results demonstrated an observable recovery of affected limb functions beginning hours after treatment commenced, suggesting that mGlu5 inhibition can reverse brain-wide disruptions in functional connectivity.
About Addex Therapeutics
Addex Therapeutics is dedicated to developing innovative solutions for neurological disorders. With a focus on novel small molecule allosteric modulators, the company is advancing its lead candidate, dipraglurant, in the pursuit of enhancing recovery outcomes in patients facing significant neurological challenges, including those from stroke and other traumatic brain injuries. Moreover, Addex collaborates with partners like Indivior, targeting treatments for substance use disorders as well as developing additional programs aimed at chronic cough.
Looking Ahead
The partnership with Sinntaxis marks a pivotal moment in Addex’s journey towards finding effective treatments for brain injury recovery. This collaboration not only enriches their pipeline but also aligns with their mission to improve the quality of life for patients affected by neurological conditions. As research progresses, Addex is set to explore the clinical viability of dipraglurant, aiming for advancements that could make a significant impact in the field of brain recovery.
Frequently Asked Questions
What is the main focus of the agreement between Addex and Sinntaxis?
The agreement centers on the licensing of mGlu5 inhibitors to enhance recovery for patients with brain injuries and the collaboration on research involving Addex’s dipraglurant.
What is dipraglurant?
Dipraglurant is an orally-active mGlu5 negative allosteric modulator being tested for its effectiveness in promoting recovery from brain injuries, particularly following strokes.
How does mGlu5 inhibition help in brain recovery?
Research shows that mGlu5 inhibition can restore lost somatosensory functions and improve neural connectivity, facilitating the brain's recovery process post-injury.
What other programs is Addex currently working on?
Addex is advancing various drug candidates focusing on neurological disorders, including collaborations on GABAB PAM programs for conditions like chronic cough and substance use disorders.
How can I stay updated on Addex's progress?
Interested individuals can visit Addex’s official website for the latest news and updates regarding their ongoing research and clinical developments.
